Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

MELBOURNE, Australia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today highlighted the potential of its lead proenzyme therapy, PRP, as a novel approach that could compete with existing approved therapies for solid tumors, particularly in areas of high unmet need such as pancreatic cancer. PRP is a proprietary intraven ...